metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	2	0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.58 [0.49; 0.70], 2 RCTs, I2=21% conclusive moderate degree of certainty	-
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1	0.79 [0.64; 0.98], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.64 [0.54; 0.76], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin	1	0.81 [0.64; 1.03], 1 RCT, I2=0% inconclusive result	0.60 [0.49; 0.73], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
	pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin	1	0.90 [0.42; 1.92], 1 RCT, I2=0% inconclusive result	0.53 [0.31; 0.91], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.49 [0.38; 0.64], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.52 [0.43; 0.63], 1 RCT, I2=0% conclusive unassessable degree of certainty	-